Popular Trials
Tyrosine Kinase Inhibitor
Lenvatinib for Adenoid Cystic Carcinoma
Recruiting1 awardPhase 2
Basking Ridge, New Jersey
This trial is testing lenvatinib, a pill that aims to stop cancer cells from growing and reduce their blood supply, in patients with adenoid cystic carcinoma. Researchers want to see if it can shrink the tumors by at least one-quarter. Lenvatinib has shown promise in treating various solid tumors, including adenoid cystic carcinoma.
Radiation Therapy
IMRT vs Proton Radiation Therapy for Sinonasal Cancer
Recruiting1 award
Boston, Massachusetts
This trial will test whether IMRT or proton radiation therapy improves local control rates and lowers toxicity compared to conventional radiation therapy in the treatment of locally advanced sinonasal malignancy.
Popular Filters
Trials for ACC Patients
Alkylating agents
9-ING-41 + Carboplatin for Salivary Gland Cancer
Recruiting2 awardsPhase 2
Boston, Massachusetts
This trial is testing a new drug called 9-ING-41 for patients with advanced salivary gland cancers that don't respond to usual treatments. The new drug aims to slow down the cancer by blocking a specific function that helps cancer cells grow.
Notch Inhibitor
AL101 Before Surgery for Adenoid Cystic Carcinoma
Recruiting1 awardPhase 1
Houston, Texas
This trial studies the effects of AL101, a drug given through an IV drip, on patients with notch activated adenoid cystic cancer. The drug aims to stop the cancer cells from growing by blocking necessary enzymes. The goal is to see if AL101 can help control this specific type of cancer before surgery.
Anti-metabolites
Pemetrexed + Pembrolizumab for Salivary Gland Cancer
Recruiting1 awardPhase 2
Scottsdale, Arizona
This trial tests the effect of combining two cancer treatments: chemotherapy drug pemetrexed with immunotherapy drug pembrolizumab. The purpose is to see if this combo is more effective than pemetrexed alone in treating patients with recurrent or metastatic salivary gland cancer.
Tyrosine Kinase Inhibitor
Lenvatinib + Pembrolizumab for Salivary Gland Cancer
Recruiting1 awardPhase 2
Miami, Florida
This trial is testing lenvatinib and pembrolizumab in patients with advanced Adenoid Cystic Carcinoma or other salivary gland cancers that have come back or spread. Lenvatinib stops cancer cells from growing, while pembrolizumab helps the immune system attack the cancer. Researchers aim to see if these drugs are effective and safe for these patients. Lenvatinib and pembrolizumab have shown promising results in treating various advanced cancers, including thyroid, liver, endometrial, and gastric cancers.
Monoclonal Antibodies
ONC-392 + Pembrolizumab for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Davis, California
This trial tests ONC-392, an antibody that helps the immune system fight cancer, in patients with advanced or spreading tumors who haven't responded to other treatments. It works by blocking a protein that usually keeps immune responses in check, making it easier for the body to attack cancer cells.
Trials for Cancer Patients
Alkylating agents
9-ING-41 + Carboplatin for Salivary Gland Cancer
Recruiting2 awardsPhase 2
Boston, Massachusetts
This trial is testing a new drug called 9-ING-41 for patients with advanced salivary gland cancers that don't respond to usual treatments. The new drug aims to slow down the cancer by blocking a specific function that helps cancer cells grow.
Notch Inhibitor
AL101 Before Surgery for Adenoid Cystic Carcinoma
Recruiting1 awardPhase 1
Houston, Texas
This trial studies the effects of AL101, a drug given through an IV drip, on patients with notch activated adenoid cystic cancer. The drug aims to stop the cancer cells from growing by blocking necessary enzymes. The goal is to see if AL101 can help control this specific type of cancer before surgery.
Monoclonal Antibodies
ONC-392 + Pembrolizumab for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Davis, California
This trial tests ONC-392, an antibody that helps the immune system fight cancer, in patients with advanced or spreading tumors who haven't responded to other treatments. It works by blocking a protein that usually keeps immune responses in check, making it easier for the body to attack cancer cells.
Trials for Metastatic Patients
Alkylating agents
9-ING-41 + Carboplatin for Salivary Gland Cancer
Recruiting2 awardsPhase 2
Boston, Massachusetts
This trial is testing a new drug called 9-ING-41 for patients with advanced salivary gland cancers that don't respond to usual treatments. The new drug aims to slow down the cancer by blocking a specific function that helps cancer cells grow.
Notch Inhibitor
AL101 Before Surgery for Adenoid Cystic Carcinoma
Recruiting1 awardPhase 1
Houston, Texas
This trial studies the effects of AL101, a drug given through an IV drip, on patients with notch activated adenoid cystic cancer. The drug aims to stop the cancer cells from growing by blocking necessary enzymes. The goal is to see if AL101 can help control this specific type of cancer before surgery.
Anti-metabolites
Pemetrexed + Pembrolizumab for Salivary Gland Cancer
Recruiting1 awardPhase 2
Scottsdale, Arizona
This trial tests the effect of combining two cancer treatments: chemotherapy drug pemetrexed with immunotherapy drug pembrolizumab. The purpose is to see if this combo is more effective than pemetrexed alone in treating patients with recurrent or metastatic salivary gland cancer.
Tyrosine Kinase Inhibitor
Lenvatinib + Pembrolizumab for Salivary Gland Cancer
Recruiting1 awardPhase 2
Miami, Florida
This trial is testing lenvatinib and pembrolizumab in patients with advanced Adenoid Cystic Carcinoma or other salivary gland cancers that have come back or spread. Lenvatinib stops cancer cells from growing, while pembrolizumab helps the immune system attack the cancer. Researchers aim to see if these drugs are effective and safe for these patients. Lenvatinib and pembrolizumab have shown promising results in treating various advanced cancers, including thyroid, liver, endometrial, and gastric cancers.
Monoclonal Antibodies
ONC-392 + Pembrolizumab for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Davis, California
This trial tests ONC-392, an antibody that helps the immune system fight cancer, in patients with advanced or spreading tumors who haven't responded to other treatments. It works by blocking a protein that usually keeps immune responses in check, making it easier for the body to attack cancer cells.
Trials With No Placebo
Alkylating agents
9-ING-41 + Carboplatin for Salivary Gland Cancer
Recruiting2 awardsPhase 2
Boston, Massachusetts
This trial is testing a new drug called 9-ING-41 for patients with advanced salivary gland cancers that don't respond to usual treatments. The new drug aims to slow down the cancer by blocking a specific function that helps cancer cells grow.
Notch Inhibitor
AL101 Before Surgery for Adenoid Cystic Carcinoma
Recruiting1 awardPhase 1
Houston, Texas
This trial studies the effects of AL101, a drug given through an IV drip, on patients with notch activated adenoid cystic cancer. The drug aims to stop the cancer cells from growing by blocking necessary enzymes. The goal is to see if AL101 can help control this specific type of cancer before surgery.
Anti-metabolites
Pemetrexed + Pembrolizumab for Salivary Gland Cancer
Recruiting1 awardPhase 2
Scottsdale, Arizona
This trial tests the effect of combining two cancer treatments: chemotherapy drug pemetrexed with immunotherapy drug pembrolizumab. The purpose is to see if this combo is more effective than pemetrexed alone in treating patients with recurrent or metastatic salivary gland cancer.
Tyrosine Kinase Inhibitor
Lenvatinib + Pembrolizumab for Salivary Gland Cancer
Recruiting1 awardPhase 2
Miami, Florida
This trial is testing lenvatinib and pembrolizumab in patients with advanced Adenoid Cystic Carcinoma or other salivary gland cancers that have come back or spread. Lenvatinib stops cancer cells from growing, while pembrolizumab helps the immune system attack the cancer. Researchers aim to see if these drugs are effective and safe for these patients. Lenvatinib and pembrolizumab have shown promising results in treating various advanced cancers, including thyroid, liver, endometrial, and gastric cancers.
Monoclonal Antibodies
ONC-392 + Pembrolizumab for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Davis, California
This trial tests ONC-392, an antibody that helps the immune system fight cancer, in patients with advanced or spreading tumors who haven't responded to other treatments. It works by blocking a protein that usually keeps immune responses in check, making it easier for the body to attack cancer cells.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.